US 12,409,322 B2
Treatment of cardiac dysfunction
Jeffrey Laurence Ardell, Oakland, CA (US); Kalyanam Shivkumar, Oakland, CA (US); and Arun Sridhar, Stevenage (GB)
Assigned to The Regents of the University of California, Oakland, CA (US); and Presidio Medical, Inc., San Francisco, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US); and Presidio Medical, Inc., South San Francisco, CA (US)
Filed on Jun. 21, 2022, as Appl. No. 17/808,087.
Application 17/808,087 is a continuation of application No. 16/328,090, granted, now 11,369,793, previously published as PCT/EP2017/071475, filed on Aug. 25, 2017.
Claims priority of provisional application 62/379,937, filed on Aug. 26, 2016.
Prior Publication US 2024/0042208 A1, Feb. 8, 2024
Int. Cl. A61N 1/36 (2006.01); A61N 1/05 (2006.01); A61N 1/32 (2006.01); A61N 1/362 (2006.01)
CPC A61N 1/36114 (2013.01) [A61N 1/0556 (2013.01); A61N 1/32 (2013.01); A61N 1/36057 (2013.01); A61N 1/362 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A device for reversibly inhibiting neural activity of a subject's cardiac-related sympathetic nerve in the extracardiac intrathoracic neural circuit of the subject, the device comprising:
at least one electrode configured to be placed on or around a cardiac-related sympathetic nerve at the ansae subclaviae or at a site along the paravertebral chain between the T1 and T2 ganglia; and
a controller configured to electrically communicate with the at least one electrode, wherein the controller is configured to deliver a therapeutic electrical signal to the at least one electrode,
wherein the therapeutic electrical signal is a kilohertz frequency alternating current (KHFAC) signal or a charge-balanced direct current (DC) signal,
wherein the therapeutic electrical signal is configured to produce a physiological response in the subject, and
wherein the physiological response is a decrease in one or more of at least chronotropic, dromotropic, lusitropic, or inotropic evoked responses.